Today as Schering-Plough unveils full-year financial results for 2007, CEO Fred Hassan is likely to be peppered with questions about how he managed the ENHANCE study of embattled cholesterol drug, Vytorin.
John Simons writes in FORTUNE:
But, for many investors who saw Hassan as an unfailing miracle-worker, his mismanagement of ENHANCE is earth shaking.
John Simons writes in FORTUNE:
But, for many investors who saw Hassan as an unfailing miracle-worker, his mismanagement of ENHANCE is earth shaking.
"It's going to take time to heal those wounds," says Leerink Swann & Company analyst Seamus Fernandez.
"There were plenty of investors who stepped into the stock while management was saying 'Don't worry about ENHANCE'."
"There were plenty of investors who stepped into the stock while management was saying 'Don't worry about ENHANCE'."
No comments:
Post a Comment